Andere talen Initiator Pharma A/S

Aandelen

INIT

DK0060775872

Beurs gesloten - Nasdaq Stockholm Andere beurzen 17:24:16 10-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
9,2 ^SEK	-0,65%		0,00%	-0,43%

23/02	Initiator Pharma A/S rapporteert resultaten voor het vierde kwartaal en het volledige jaar eindigend op 31 december 2023	CI
21/02	Initiator Pharma geeft nieuwe aandelen uit voor schuldconversie	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Initiator Pharma Q1 2024 - Focus on sealing a deal	10/05
INITIATOR PHARMA: Q1 2024 REPORT	10/05
Notice to AGM in Initiator Pharma	02/05
Annual report and Remuneration report 2023 for Initiator Pharma A/S	02/05
Initiator Pharma's pudafensine preclinical pharmacology results published in the British Journal of Pharmacology	15/04
Initiator Pharma’s pudafensine preclinical pharmacology results published in the British Journal of Pharmacology	12/04
Initiator Pharma - Q4 2023 – Breathing optimism	23/02
INITIATOR PHARMA: YEAR END REPORT 2023	23/02
Initiator Pharma A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	23/02
Initiator Pharma Issues New Shares for Debt Conversion	21/02
MAC Clinical Research converts its receivable into shares in Initiator Pharma	21/02
Initiator Pharma A/S - Issuance of new shares and directed share buyback, as well as the sale of shares in connection with the long-term incentive program for 2021	24/01
Issuance of new shares and directed share buyback, as well as the sale of shares in connection with the long-term incentive program for 2021	23/01
Initiator Pharma expands its position to a broader Sexual Health Franchise and intensifies its business development efforts	08/01
Initiator Pharma A/S Expands Its Position to Broader Sexual Health Franchise and Intends Business Development Efforts	08/01
Initiator Pharma Q3 - A historical quarter	10/11
Initiator Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11
Initiator Pharma reports positive statistically significant and clinically relevant Phase IIb efficacy data with pudafensine	07/11
Initiator Pharma - Positive Phase IIb results	10-10-23
Initiator Pharma reports positive statistically significant and clinically relevant Phase IIb efficacy data with pudafensine	09-10-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Initiator Pharma A/S

Aandelen

INIT

DK0060775872

Andere talen

Filters